We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Sino Biological, Inc. to be Featured on Worldwide Business with Kathy Ireland®

Sino Biological, Inc. to be Featured on Worldwide Business with Kathy Ireland® content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Sino Biological, Inc.  (“Sino Biological” or the “Company”), a biotechnology company which provides biological research reagents and related technical contract research services, will be featured on Worldwide Business with kathy ireland®, airing on FOX Business Network, Bloomberg International and other outlets as sponsored content. Hosted by business mogul Kathy Ireland, this award-winning television series takes an in-depth look at companies around the world currently impacting different sectors of business and society. Dr. Rob Burgess, Chief Business Officer for Sino Biological, will be interviewed.

“It’s exciting and quite an honor to have an opportunity to be interviewed by Kathy Ireland on Worldwide Business and to share the corporate vision that we have at Sino Biological. I’m also delighted with the chance to outline the company’s global impact on human health and biomedical research and I look forward to describing how Sino Biological’s offering helps to drive advances in biomedical research and promote the research and development of innovative drugs, vaccines and diagnostic tests,” stated Dr. Burgess. 

“Sino Biological Incorporated is providing value-added, cost-effective solutions and is turning scientific advances into reality,” stated Kathy Ireland.

Forward-Looking Statements

Certain statements in the Worldwide Business with kathy ireland® segment and this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, over which Biological has no control. Sino Biological assumes no obligation to update these forward-looking statements and does not intend to do so.